Axsome Therapeutics Inc (AXSM) is a Healthcare · Biotechnology company listed on NASDAQ. Price $209.20 (-2.37%), Market cap $12.02B, 52-week low–high $100.39 ~ $235.97.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbr
Financial statements, price targets, institutional (13F) holdings and related news for Axsome Therapeutics Inc are updated in real time on BlackAll Trade.
Axsome Therapeutics Inc trades at $209.20 (-2.37%). Real-time quotes and charts are available on BlackAll Trade.
Axsome Therapeutics Inc has a market cap of about $12.02B.
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercia